"Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo And Ustekinumab"
Inside Information - UCB, a global biopharmaceutical company, today announced positive results from BE VIVID, the first of three Phase 3 studies evaluating the efficacy and safety of bimekizumab, an IL-17A and IL-17F inhibitor, in the treatment of adults with moderate-to-severe chronic plaque psoriasis. “These encouraging first results provide strong evidence that bimekizumab has the potential to raise the bar for achieving skin clearance rates for patients. Achieving clear skin is of critical importance in positively impacting the lives of psoriasis patients,” said lead study investigator Mark Lebwohl, MD, chair of the department of dermatology at the Mount Sinai Health System. He added, “Today’s announcement marks an important milestone in the extensive clinical development of bimekizumab.”
— Mark G. Lebwohl, MD, Professor, Dermatology, Icahn School of Medicine at Mount Sinai, Chair, Waldman Department of Dermatology, Mount Sinai Health System